Effects of recombinant human thrombopoietin combined with Cyclosporine in treatment of children with aplastic anemia
Objective:To observe effects of recombinant human thrombopoietin combined with Cyclosporine in treatment of children with aplastic anemia(AA).Methods:The clinical data of 60 children with AA admitted to this hospital from January 2020 to April 2023 were retrospectively analyzed.According to different treatment methods,they were divided into control group and observation group,30 cases in each group.The control group was treated with Cyclosporine,while the observation group was treated with recombinant human thrombopoietin on the basis of that of the control group.The clinical efficacy,the platelet count(PLT)recovery time,the clinical indicators(bone marrow megakaryocyte count,platelet transfusion volume,granulocyte implantation time)levels,the vascular endothelial growth factor-C(VEGF-C)levels,the oxidative stress indicators[reduced glutathione(GSH),superoxide dismutase(SOD),catalase(CAT),malondialdehyde(MDA)]levels,and the incidence of adverse reactions were compared between the two groups before and after the treatment.Results:The total effective rate of the observation group was 96.67%(29/30),which was higher than 66.67%(20/30)of the control group,and the difference was statistically significant(P<0.05).There was no statistically significant difference in the recovery time of PLT≥20×109/L between two groups(P>0.05).The recovery time of PLT≥50×109/L and PLT≥100×109/L in the observation group was shorter than that in the control group,and the difference was statistically significant(P<0.05).The bone marrow megakaryocyte count in the observation group was higher than that in the control group,the platelet transfusion volume was less than that in the control group,the granulocyte implantation time was shorter than that in the control group,and the differences were statistically significant(P<0.05).After the treatment,the level of VEGF-C in the observation group was higher than that in the control group,the difference was statistically significant(P<0.05).After the treatment,the level of MDA in the observation group was lower than that in the control group,the levels of CAT,GSH and SOD were higher than those in the control group,and the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Recombinant human thrombopoietin combined with Cyclosporine in the treatment of the children with AA can improve the total effective rate and the VEGF-C levels,shorten the recovery time of PLT,and improve the levels of clinical indicators and oxidative stress indicators.Moreover,it is superior to single Cyclosporine treatment.
Aplastic anemiaRecombinant human thrombopoietinCyclosporinePlatelet recovery timeOxidative stressVascular endothelial growth factor-C
NETL
NSTL
万方数据
